Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Clene Inc.

Get SEC filing alerts via email and in your feed for Clene Inc.

CLNN CLNNW

Clene Inc.

About Clene Inc.

Clene Inc. is a clinical-stage pharmaceutical company developing innovative nanotechnology-based therapeutics targeting neurodegenerative and infectious diseases. Its proprietary clean-surfaced nanocrystals support cellular energy, reduce oxidative stress, and address protein aggregation. Focused on CNS disorders like ALS, MS, and Parkinson’s, the company aims to revolutionize treatment through catalytically active nanocrystals with broad applicability and multi-modal mechanisms of action.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Clene Inc.

1
1
Clene Inc. Clene Inc. Reports 81% Revenue Decline and $8.1 Million Net Loss in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Clene Inc. Clene Inc. Reports $26.2 Million Net Loss and Decreased Revenue in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Clene Inc. Clene Inc. Reports 83% Revenue Decline in Q3 2025, Faces Financial Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Clene Inc. Clene Inc. Reports 70% Revenue Decline in Q2 2025, Plans for Funding Options

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Clene Inc. Clene Inc. Reports 11% Revenue Growth and Significant Reduction in Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Clene Inc. Clene Inc. Reports $39.4 Million Net Loss for 2024, Revenue Decreases by 48%

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Clene Inc. Clene Inc. Reports Mixed Financial Results for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments